Bristol-Myers Squibb has joined with digital therapeutics firm Voluntis to create an app that will support cancer patients. In the last decade, BMS has emerged as a leader in the field of ...
The drug combo of daclatasvir from BMS and Gilead’s GS-7977 reached a 100% sustained virologic response (SVR), or cure rate, at week four in one common subgroup, genotype 1 patients who have not been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback